Pub Date : 2015-06-10DOI: 10.17554/j.issn.2309-6861.2014.02.583
B. Marion, L. Benoit, Akodad Mariama, Monnin Valerie, Roubille François
“We report the case of a 26-years-old man hospitalized with a typical clinical presentation of Mumps. Indeed, he was admitted for epiglottitis and developed during his hospitalization an orchiepididymitis, a pancreatitis and a rare but well-known complication of this infection: myocarditis confirmed by Cardiac MRI.
{"title":"A Rare Case of Mumps Myocarditis","authors":"B. Marion, L. Benoit, Akodad Mariama, Monnin Valerie, Roubille François","doi":"10.17554/j.issn.2309-6861.2014.02.583","DOIUrl":"https://doi.org/10.17554/j.issn.2309-6861.2014.02.583","url":null,"abstract":"“We report the case of a 26-years-old man hospitalized with a typical clinical presentation of Mumps. Indeed, he was admitted for epiglottitis and developed during his hospitalization an orchiepididymitis, a pancreatitis and a rare but well-known complication of this infection: myocarditis confirmed by Cardiac MRI.","PeriodicalId":92802,"journal":{"name":"Journal of clinical cardiology and cardiovascular therapy","volume":"18 1","pages":"329-331"},"PeriodicalIF":0.0,"publicationDate":"2015-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90289617","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2015-06-10DOI: 10.17554/j.issn.2309-6861.2014.02.584
G. Malclès, R. Eschalier, C. Dauphin, J. Lusson
We report a case of isolated pulmonary native valve infectious endocarditis due to staphylococcus hominis in a patient without predisposing factors. Multimodality imaging is essential to diagnose and manage this uncommon clinical entity.
{"title":"Multimodality Imaging of an Isolated Pulmonary Native Valve Infective Endocarditis Due to Staphylococcus Hominis","authors":"G. Malclès, R. Eschalier, C. Dauphin, J. Lusson","doi":"10.17554/j.issn.2309-6861.2014.02.584","DOIUrl":"https://doi.org/10.17554/j.issn.2309-6861.2014.02.584","url":null,"abstract":"We report a case of isolated pulmonary native valve infectious endocarditis due to staphylococcus hominis in a patient without predisposing factors. Multimodality imaging is essential to diagnose and manage this uncommon clinical entity.","PeriodicalId":92802,"journal":{"name":"Journal of clinical cardiology and cardiovascular therapy","volume":"27 1","pages":"332-333"},"PeriodicalIF":0.0,"publicationDate":"2015-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81002097","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2015-06-10DOI: 10.17554/j.issn.2309-6861.2015.02.581
B. Lattuca, F. Leclercq, J. Macia, R. Gervasoni, T. Cung, J. Pasquié, F. Massin, S. Cade, F. Cransac, Mariama Akodad, F. Roubille
Colchicine is a venerable drug used for centuries for rheumatic diseases with potential pleiotropic anti-inflammatory effects. One of the main concerns remains the tolerability especially digestive side effects, but this aspect has been improved by many pharmacological improvements. Nowadays, colchine is a promising drug for cancer therapy and cardiovascular diseases with several studies currently going on, an improved therapeutic window and a wider range of translations in cardioprotection but also in atrial fibrillation, ischemic cardiopathy or pericarditis.
{"title":"Colchicine: A Promising Drug in Clinical Translation, A Minireview Focused on Cardiovascular Diseases","authors":"B. Lattuca, F. Leclercq, J. Macia, R. Gervasoni, T. Cung, J. Pasquié, F. Massin, S. Cade, F. Cransac, Mariama Akodad, F. Roubille","doi":"10.17554/j.issn.2309-6861.2015.02.581","DOIUrl":"https://doi.org/10.17554/j.issn.2309-6861.2015.02.581","url":null,"abstract":"Colchicine is a venerable drug used for centuries for rheumatic diseases with potential pleiotropic anti-inflammatory effects. One of the main concerns remains the tolerability especially digestive side effects, but this aspect has been improved by many pharmacological improvements. Nowadays, colchine is a promising drug for cancer therapy and cardiovascular diseases with several studies currently going on, an improved therapeutic window and a wider range of translations in cardioprotection but also in atrial fibrillation, ischemic cardiopathy or pericarditis.","PeriodicalId":92802,"journal":{"name":"Journal of clinical cardiology and cardiovascular therapy","volume":"43 1","pages":"311-314"},"PeriodicalIF":0.0,"publicationDate":"2015-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75090202","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2015-06-10DOI: 10.17554/j.issn.2309-6861.2015.02.582
C. Camille, J. Martel-Pelletier, J. Sellam, J. Pelletier, J. Raynauld, F. Roubille
Osteoarthritis (OA) was found associated with atherosclerosis, metabolic syndrome, more cardiovascular diseases (CVD) and higher cardiovascular morbidity and mortality. However, it remains unclear whether these conditions only coexist in ageing patients presenting shared traditional cardiovascular risk factors, including age, obesity and disability-related sedentary lifestyle, or are further interconnected. Interestingly, the accumulation of metabolic syndrome components was associated with the development and progression of knee OA, supporting the concept of metabolic OA. Recent research suggests key roles of meta-inflammation, and adipokines in the pathogenesis of OA, metabolic syndrome and CVD. While leptin may be one cornerstone mediator linking obesity, metabolic syndrome, OA, and CVD, the exact role of adiponectin remains controversial in both CVD and OA as it may exert both pro-inflammatory and anti-inflammatory properties. However, the relationship between adipokines and OA as well as CVD is being uncovered and require further investigation. In any case, if meta-inflammation is truly the pivotal link interconnecting OA, metabolic syndrome, and CVD, managing dyslipidemia, hyperglycemia, hypertension and weight in OA patients may be beneficial not only for cardiovascular reasons but also perhaps to delay OA progression.
{"title":"Osteoarthritis and Cardiovascular Diseases: is Meta-Inflammation the Missing Link?","authors":"C. Camille, J. Martel-Pelletier, J. Sellam, J. Pelletier, J. Raynauld, F. Roubille","doi":"10.17554/j.issn.2309-6861.2015.02.582","DOIUrl":"https://doi.org/10.17554/j.issn.2309-6861.2015.02.582","url":null,"abstract":"Osteoarthritis (OA) was found associated with atherosclerosis, metabolic syndrome, more cardiovascular diseases (CVD) and higher cardiovascular morbidity and mortality. However, it remains unclear whether these conditions only coexist in ageing patients presenting shared traditional cardiovascular risk factors, including age, obesity and disability-related sedentary lifestyle, or are further interconnected. Interestingly, the accumulation of metabolic syndrome components was associated with the development and progression of knee OA, supporting the concept of metabolic OA. Recent research suggests key roles of meta-inflammation, and adipokines in the pathogenesis of OA, metabolic syndrome and CVD. While leptin may be one cornerstone mediator linking obesity, metabolic syndrome, OA, and CVD, the exact role of adiponectin remains controversial in both CVD and OA as it may exert both pro-inflammatory and anti-inflammatory properties. However, the relationship between adipokines and OA as well as CVD is being uncovered and require further investigation. In any case, if meta-inflammation is truly the pivotal link interconnecting OA, metabolic syndrome, and CVD, managing dyslipidemia, hyperglycemia, hypertension and weight in OA patients may be beneficial not only for cardiovascular reasons but also perhaps to delay OA progression.","PeriodicalId":92802,"journal":{"name":"Journal of clinical cardiology and cardiovascular therapy","volume":"9 1","pages":"315-320"},"PeriodicalIF":0.0,"publicationDate":"2015-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81830955","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2015-06-10DOI: 10.17554/j.issn.2309-6861.2015.02.587
K. Solecki, B. Lattuca, F. Leclercq, R. Gervasoni, J. Macia, T. Cung, F. Cransac, S. Cade, J. Davy, Y. Dauvilliers, F. Roubille
Obstructive sleep apnoea (OSA) is recognized as an important cardiovascular risk factor and is intricate with coronary disease. OSA could be involved in worsening the cardiac remodeling following the acute myocardial infarction (AMI). Cardiac remodeling is an important determinant of the clinical outcome of heart failure and is linked to disease progression and poor prognosis. The aims of this minireview are to address the frequency reported in the literature of OSA in patients with AMI and to summarize the main mechanisms of cardiac remodeling by OSA and its consequences on cardiovascular system. In addition, we aim to identify new strategies in the management of AMI. OSA is frequent in patients with AMI. OSA may have a role in cardiac remodeling after AMI and especially in relationship with the increased sensitivity of the reperfused tissue to all underlying mechanisms: a complex interplay of mechanical or haemodynamic factors, reactive oxygen species balance, sympathetic nerve activity, endothelial dysfunction, proinflammatory factors and coagulation abnormalities. Continuous positive airway pressure CPAP might represent a non pharmalogical treatment in addition to the global management of patients with AMI.
{"title":"Ventricular Remodeling after Myocardial Infarct: A Minireview on the Impact of Obstructive Sleep Apnea Syndrome","authors":"K. Solecki, B. Lattuca, F. Leclercq, R. Gervasoni, J. Macia, T. Cung, F. Cransac, S. Cade, J. Davy, Y. Dauvilliers, F. Roubille","doi":"10.17554/j.issn.2309-6861.2015.02.587","DOIUrl":"https://doi.org/10.17554/j.issn.2309-6861.2015.02.587","url":null,"abstract":"Obstructive sleep apnoea (OSA) is recognized as an important cardiovascular risk factor and is intricate with coronary disease. OSA could be involved in worsening the cardiac remodeling following the acute myocardial infarction (AMI). Cardiac remodeling is an important determinant of the clinical outcome of heart failure and is linked to disease progression and poor prognosis. The aims of this minireview are to address the frequency reported in the literature of OSA in patients with AMI and to summarize the main mechanisms of cardiac remodeling by OSA and its consequences on cardiovascular system. In addition, we aim to identify new strategies in the management of AMI. OSA is frequent in patients with AMI. OSA may have a role in cardiac remodeling after AMI and especially in relationship with the increased sensitivity of the reperfused tissue to all underlying mechanisms: a complex interplay of mechanical or haemodynamic factors, reactive oxygen species balance, sympathetic nerve activity, endothelial dysfunction, proinflammatory factors and coagulation abnormalities. Continuous positive airway pressure CPAP might represent a non pharmalogical treatment in addition to the global management of patients with AMI.","PeriodicalId":92802,"journal":{"name":"Journal of clinical cardiology and cardiovascular therapy","volume":"51 Suppl 1 1","pages":"321-328"},"PeriodicalIF":0.0,"publicationDate":"2015-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"91007832","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2014-07-10DOI: 10.17352/2455-2976.000004
A. Mazza, S. Valsecchi, U. Riva, M. G. Bendini, M. Leggio
Heart Failure is the result of heterogeneous structural heart diseases, especially ischemic disease, and is becoming increasingly common in all Western countries. Many patients continue to be symptomatic in spite of progress in pharmacological therapy, and the risk of mortality remains high in the most advanced functional classes. Cardiac resynchronization therapy can be used as a therapeutic strategy for alleviating symptoms and reducing mortality in a considerable percentage of patients with heart failure.Cardiac resynchronization therapy provides both immediate and medium/long-term results. The immediate results are the reduced QRS duration, the synchrony restoration between the ventricles and between the lateral and septal walls of the left ventricle, the reduced mitral regurgitation and the increased stroke volume. In the medium/long term, left ventricular reverse remodeling occurs and left ventricular ejection fraction is increased. Several trials have documented both increased functional capacity and improvements in quality of life and New York Heart Association class. Moreover, cardiac resynchronization therapy has been seen to reduce HF hospitalizations and mortality and the total number of days of hospitalization. In order to reduce the percentage of non-responders to cardiac resynchronization therapy, it is necessary to optimize the prognostic stratification of candidates for implantation through multi-parameter evaluations and to ensure correct device programming with periodic updates which are widely recommended but not so often performed. Whether indications should be extended will need to be evaluated in view of the known complications mainly associated with lead implantation.
{"title":"Cardiac Resynchronization Therapy in Heart Failure: Rationale, Results, Indications, Limits and Perspectives","authors":"A. Mazza, S. Valsecchi, U. Riva, M. G. Bendini, M. Leggio","doi":"10.17352/2455-2976.000004","DOIUrl":"https://doi.org/10.17352/2455-2976.000004","url":null,"abstract":"Heart Failure is the result of heterogeneous structural heart diseases, especially ischemic disease, and is becoming increasingly common in all Western countries. Many patients continue to be symptomatic in spite of progress in pharmacological therapy, and the risk of mortality remains high in the most advanced functional classes. Cardiac resynchronization therapy can be used as a therapeutic strategy for alleviating symptoms and reducing mortality in a considerable percentage of patients with heart failure.Cardiac resynchronization therapy provides both immediate and medium/long-term results. The immediate results are the reduced QRS duration, the synchrony restoration between the ventricles and between the lateral and septal walls of the left ventricle, the reduced mitral regurgitation and the increased stroke volume. In the medium/long term, left ventricular reverse remodeling occurs and left ventricular ejection fraction is increased. Several trials have documented both increased functional capacity and improvements in quality of life and New York Heart Association class. Moreover, cardiac resynchronization therapy has been seen to reduce HF hospitalizations and mortality and the total number of days of hospitalization. In order to reduce the percentage of non-responders to cardiac resynchronization therapy, it is necessary to optimize the prognostic stratification of candidates for implantation through multi-parameter evaluations and to ensure correct device programming with periodic updates which are widely recommended but not so often performed. Whether indications should be extended will need to be evaluated in view of the known complications mainly associated with lead implantation.","PeriodicalId":92802,"journal":{"name":"Journal of clinical cardiology and cardiovascular therapy","volume":"16 1","pages":"121-126"},"PeriodicalIF":0.0,"publicationDate":"2014-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75349722","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：